There is a reason Bruce Vanyo's peers call him the "dean of securities litigation." He has spent more than 40 years handling securities fraud and corporate governance lawsuits for clients such as Amarin Corporation, Amdocs, Inc., Angie's List, Boeing Company, Cree, Inc. and GW Pharmaceuticals — and succeeding on their behalf. Leading the firm's securities litigation and enforcement practice, Bruce represents clients across a number of industries, particularly technology and life sciences.
Bruce has "defended more major securities cases than any other lawyer in America," as the National Association of Corporate Directors has said. He represents clients who are in the midst of high-profile, sensitive cases that demand a deft approach and swift resolution. He makes it a priority to stop these lawsuits at the earliest opportunity, and regularly achieves this outcome. Of the more than 60 securities class actions Bruce has resolved over the past two decades, he has obtained complete dismissal at or before the pleading stage in more than three-quarters of them.
By resolving cases efficiently, Bruce minimizes distractions for his clients and allows them to focus on running their businesses. His approach also controls the potentially burdensome costs of litigation. A number of Bruce's victories have favorably influenced securities law for defendants. He recently earned the dismissal of an $800 million securities class action, for instance, that clarified and limited a company's disclosure requirements with regard to the FDA's drug approval process. When the technology industry was besieged by class actions, he was tapped to lead its securities litigation reform efforts, creating the pleading and safe harbor provisions of the Private Securities Litigation Reform Act of 1995.